CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
17 Febrero 2021 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational conditionally-active antibody therapeutics based
on its Probody® technology platform, today announced that it will
report fourth quarter and full year 2020 financial results
on Wednesday, February 24, 2021, after the close of U.S.
markets. Following the announcement, the Company will host a
conference call and webcast at 5:00 p.m. ET / 2:00
p.m. PT to discuss the results and provide a corporate update.
Participants may access the live webcast of the
conference call from the Events and Presentations page of CytomX’s
website at www.cytomx.com. An archived replay of the webcast
will be available on the Company's website until March 3, 2021.
Audio Conference Call:
|
U.S. Dial-in
Number: |
(877)
809-6037 |
|
|
|
|
International Dial-in Number: |
(615) 247-0221 |
|
|
|
|
Conference ID: |
5558715 |
About CytomX TherapeuticsCytomX
is a clinical-stage, oncology-focused biopharmaceutical company
with a vision of transforming lives with safer, more effective
therapies. We are developing a novel class of investigational
conditionally-active antibody therapeutics, based on our Probody®
technology platform, for the treatment of cancer. CytomX has
strategic drug discovery and development collaborations with
AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody therapeutics are conditionally-active
antibodies designed to remain inactive until they are activated by
proteases in the tumor microenvironment. As a result, Probody
therapeutics are intended to bind selectively to tumors and
decrease binding to healthy tissue, to minimize toxicity and
potentially create safer, more effective therapies. As leaders in
the field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential first-in-class therapeutic
candidates against novel, difficult to drug targets and potential
best-in-class immunotherapeutic candidates against clinically
validated targets. The CytomX clinical-stage pipeline comprises
five assets, four of which are in Phase 2 clinical studies.
First-in-class product candidates against previously undruggable
targets include a CD166-targeting conditionally-active
antibody-drug conjugate wholly owned by CytomX (praluzatamab
ravtansine, CX-2009) and a CD71-targeting conditionally-active
antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets that are considered to be
inaccessible to conventional antibody-drug conjugates due to their
presence on many healthy tissues. The CytomX clinical-stage
pipeline also includes cancer immunotherapeutic candidates against
validated targets such as the CTLA-4-targeting conditionally-active
antibody therapeutics, BMS-986249 and BMS-986288, partnered with
Bristol Myers Squibb, and our wholly-owned conditionally-active
anti-PD-L1 antibody, pacmilimab (CX-072). For additional
information about CytomX Therapeutics, visit www.cytomx.com and
follow us on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements, including
those relating to the potential benefits, safety and efficacy or
progress of CytomX’s or any of its collaborative partners’ product
candidates, including praluzatamab ravtansine, CX-2029, BMS-986249
and BMS-986288, the potential benefits or applications of CytomX’s
Probody platform technology, CytomX’s ability to develop and
advance product candidates into and successfully complete clinical
trials, including the ongoing and planned clinical trials of
praluzatamab ravtansine, CX-2029, BMS-986249 and BMS-986288, and
the timing of the commencement of clinical trials and other
development milestones. Risks and uncertainties that contribute to
the uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the risk that the COVID-19 worldwide
pandemic may continue to negatively impact the business, research
and clinical operations of CytomX or its partners, including the
development of preclinical drug candidates due to delays in and
disruption of research activities and the development of clinical
drug candidates due to delays in or disruption of clinical trials,
including impacts on the enrollment of patients in clinical trials
or other clinical trial disruptions; the possibility that the
results of early clinical trials may not be predictive of future
results; the possibility that CytomX’s clinical trials will not be
successful; the possibility that current preclinical research may
not result in additional product candidates; CytomX’s dependence on
the success of praluzatamab ravtansine, CX-2029, BMS-986249,
BMS-986288, and pacmilimab; CytomX’s reliance on third parties for
the manufacture of the company’s product candidates; and possible
regulatory developments in the United States and foreign
countries. Additional applicable risks and uncertainties include
those relating to our preclinical research and development,
clinical development, and other risks identified under the heading
"Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q
filed with the SEC on November 5, 2020. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
CytomX Contact:Chau Cheng, PhD
MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.comDirect: (650) 273-4999
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com 212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024